Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACCE: Panitumumab with Chemotherapy and Bevacizumab in mCRC
NCT00115765Phase 3Completed
- Sponsor
- Amgen
- Start
- Jun 2005
- Primary completion
- May 2007
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial of panitumumab in metastatic colorectal cancer (mCRC) (4 arms), sponsored by Amgen. Primary endpoints: Progression-Free Survival (Oxaliplatin) and Objective Tumor Response Through Week 12 (Irinotecan). Started Jun 2005; status: completed.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00115765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115765.